Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy

Phase 3

Completed

• Conditions: Hodgkin Disease
• Interventions: Drug: Filgrastim SD/01; Drug: Adriamycin; Drug: Bleomycin; Drug: Vinblastine; Drug: DTIC

• Registration Number: NCT00038558
• Lead Sponsor: M.D. Anderson Cancer Center

Brief Summary

Prophylactic use of Filgrastim SD/01 for patients with Hodgkin's lymphoma receiving ABVD chemotherapy.

Detailed Description

Not available

Study Timeline

• Study Start: 2001-11
• Study First Submitted: 2002-05-31
• Study First Submitted QC: 2002-05-31
• Study First Posted: 2002-06-03
• Primary Completion: 2004-02
• Study Completion: 2005-03
• Status Verified: 2018-10
• Last Update Submitted: 2018-10-30
• Last Update Posted: 2018-10-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Filgrastim + ABVD Chemotherapy	Filgrastim SD/01	-
Filgrastim + ABVD Chemotherapy	Adriamycin	-
Filgrastim + ABVD Chemotherapy	Bleomycin	-
Filgrastim + ABVD Chemotherapy	Vinblastine	-
Filgrastim + ABVD Chemotherapy	DTIC	-

Primary Outcome Measures

Name	Time	Method
Number of Patients with Response to Prophylactic Filgrastim SD/01Chemotherapy	Following ABVD chemotherapy course

Trial Locations

Locations (1)

UT MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States